KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback